Showing results (401-410 of 423) with videos related to

Sort By:
Pageof 43
Endocrine-Related Cancer|January 7, 2015
HES5 silencing is an early and recurrent change in prostate tumourigenesisCharles E Massie, Inmaculada Spiteri, Helen Ross-Adams, et al.
Arthritis Research & Therapy|February 6, 2021
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studyJonathan Kay, Janusz Jaworski, Rafal Wojciechowski, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Rheumatology (Oxford, England)|June 18, 2021
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritisDaniel E Furst, Janusz Jaworski, Rafal Wojciechowski, et al.
Annals of the Rheumatic Diseases|April 16, 2025
Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024Kevin L Winthrop, Joan Bathon, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases|February 4, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, et al.
Nature Genetics|September 29, 2022
The NALCN channel regulates metastasis and nonmalignant cell disseminationEric P Rahrmann, David Shorthouse, Amir Jassim, et al.
European Urology|November 18, 2015
The Early Effects of Rapid Androgen Deprivation on Human Prostate CancerGreg L Shaw, Hayley Whitaker, Marie Corcoran, et al.
Annals of the Rheumatic Diseases|October 8, 2013
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)Maxime Dougados, Martin Soubrier, Anna Antunez, et al.
Pageof 43